Heron Therapeutics, Inc. (HRTX)

Name: Heron Therapeutics, Inc. (HRTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name HERON THERAPEUTICS, INC. /DE/ · CIK 0000818033 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Heron Therapeutics, Inc. reported revenue of $154.90M. Revenue grew 7.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $151.18M.

Key ratios (year ended 2025-12-31)

73.3%

Gross margin

-1.6%

Operating margin

-13.0%

Net margin

-140.9%

Return on year-end equity

7.4%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-29

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$151.18M	$154.90M	$144.28M	$127.04M	$107.67M	$86.35M	$88.64M	$145.97M	$77.47M	$30.77M	$1.28M
Cost of Revenue	$45.24M	$41.35M	$38.65M	$65.11M	$54.87M	$46.02M	$36.19M	$61.62M	$27.51M	$4.59M	$35.0K
Gross Profit	$105.94M	$113.56M	$105.64M	$61.94M	$52.80M	$40.33M	$52.45M	$84.35M	$49.96M	$26.18M	n/a
R&D Expense	$12.30M	$12.43M	$16.68M	$39.13M	$82.70M	$130.82M	$174.53M	$167.38M	$140.03M	$138.58M	$103.12M
Operating Income	-$10.86M	-$2.54M	-$11.53M	-$110.61M	-$174.66M	-$217.83M	-$228.16M	-$210.69M	-$183.94M	-$194.56M	-$170.91M
Depreciation & Amortization	$2.13M	$2.31M	$2.49M	$2.90M	$2.89M	$3.02M	$2.85M	$2.04M	$1.51M	$1.53M	$1.10M
EBITDA	-$8.73M	-$224.0K	-$9.04M	-$107.72M	-$171.77M	-$214.81M	-$225.32M	-$208.65M	-$182.42M	-$193.03M	-$169.82M
Net Income	-$34.05M	-$20.20M	-$13.58M	-$110.56M	-$182.02M	-$220.68M	-$227.28M	-$204.75M	-$178.84M	-$197.48M	-$173.14M
EPS (Diluted)	n/a	-$0.12	-$0.09	-$0.80	-$1.67	-$2.24	n/a	n/a	n/a	n/a	n/a
Total Assets	$252.26M	$255.88M	$233.15M	$222.51M	$250.95M	$305.71M	$353.56M	$512.78M	$462.18M	$234.31M	$67.48M
Total Liabilities	$245.35M	$241.54M	$266.80M	$256.48M	$237.38M	$228.14M	$117.06M	$108.95M	$92.02M	$103.17M	$88.73M
Shareholders' Equity	$6.91M	$14.33M	-$33.65M	-$33.97M	$13.57M	$77.57M	$236.49M	$403.83M	$370.16M	$131.14M	-$21.25M
Cash & Equivalents	$20.72M	$28.65M	$25.80M	$28.68M	$15.36M	$90.54M	$105.14M	$71.90M	$31.84M	$144.58M	$13.41M
Operating Cash Flow	-$11.61M	-$27.59M	-$22.53M	-$58.79M	-$146.91M	-$203.35M	-$184.82M	-$124.58M	-$191.81M	-$170.30M	-$134.10M
Capital Expenditures	$529.0K	$317.0K	$1.71M	$1.54M	$1.82M	$3.02M	$6.81M	$7.15M	$9.17M	$2.55M	$3.13M
Free Cash Flow	-$12.13M	-$27.91M	-$24.23M	-$60.33M	-$148.74M	-$206.38M	-$191.63M	-$131.73M	-$200.98M	-$172.85M	-$137.23M
Shares Outstanding	n/a	188.31M	152.13M	150.29M	119.15M	102.00M	91.31M	90.30M	78.17M	64.61M	39.4K
Weighted Average Diluted Shares	n/a	166.71M	152.45M	138.13M	108.88M	n/a	n/a	n/a	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.12	-$0.09	-$0.80	-$1.67	-$2.24	n/a	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView